Skip to main content
NHLBIHIN

Archived page

National Cholesterol Education Program

Adult Treatment Panel III (ATP III) Guidelines Slide Set

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13

Return to Menu



SLIDE 1: ATP III Guidelines
Specific Dyslipidemias

 Return to Top

SLIDE 2: Specific Dyslipidemias: Very High LDL Cholesterol (greater than or equal to190 mg/dL)
Causes and Diagnosis

  • Genetic disorders
    • Monogenic familial hypercholesterolemia
    • Familial defective apolipoprotein B-100
    • Polygenic hypercholesterolemia
  • Family testing to detect affected relatives

 Return to Top

SLIDE 3: Specific Dyslipidemias: Very High LDL Cholesterol (greater than or equal to190 mg/dL) (continued)
Management

  • LDL-lowering drugs
    • Statins (higher doses)
    • Statins + bile acid sequestrants
    • Statins + bile acid sequestrants + nicotinic acid

 Return to Top

SLIDE 4: Specific Dyslipidemias: Elevated Triglycerides
Classification of Serum Triglycerides

  • Normal <150 mg/dL
  • Borderline high 150-199 mg/dL
  • High 200-499 mg/dL
  • Very high greater than or equal to500 mg/dL

 Return to Top

SLIDE 5: Specific Dyslipidemias: Elevated Triglycerides (greater than or equal to150 mg/dL)
Causes of Elevated Triglycerides

  • Obesity and overweight
  • Physical inactivity
  • Cigarette smoking
  • Excess alcohol intake

 Return to Top

SLIDE 6: Specific Dyslipidemias: Elevated Triglycerides
Causes of Elevated Triglycerides (continued)

  • High carbohydrate diets (>60% of energy intake)
  • Several diseases (type 2 diabetes, chronic renal failure, nephrotic syndrome)
  • Certain drugs (corticosteroids, estrogens, retinoids, higher doses of beta-blockers)
  • Various genetic dyslipidemias

 Return to Top

SLIDE 7: Specific Dyslipidemias: Elevated Triglycerides (continued)
Non-HDL Cholesterol: Secondary Target

  • Non-HDL cholesterol=VLDL + LDL cholesterol=(Total Cholesterol - HDL cholesterol)
  • VLDL cholesterol: denotes atherogenic remnant lipoproteins
  • Non-HDL cholesterol: secondary target of therapy when serum triglycerides are greater than or equal to200 mg/dL (esp. 200-499 mg/dL)
  • Non-HDL cholesterol goal: LDL-cholesterol goal + 30 mg/dL

 Return to Top

SLIDE 8: >Comparison of LDL Cholesterol and Non-HDL Cholesterol Goals for Three Risk Categories

Risk Category LDL-C Goal (mg/dL) Non-HDL-C Goal (mg/dL)
CHD and CHD Risk Equivalent (10-year risk for CHD >20% <100 >130
Multiple (2+) Risk Factors and 10-year risk <20% >130 .160
0-1 Risk Factor <160 <190

 Return to Top

SLIDE 9: Specific Dyslipidemias: Elevated Triglycerides
Non-HDL Cholesterol: Secondary Target

  • Primary target of therapy: LDL cholesterol
  • Achieve LDL goal before treating non-HDL cholesterol
  • Therapeutic approaches to elevated non-HDL cholesterol
    • Intensify therapeutic lifestyle changes
    • Intensify LDL-lowering drug therapy
    • Nicotinic acid or fibrate therapy to lower VLDL

 Return to Top

SLIDE 10: Specific Dyslipidemias: Elevated Triglycerides
Management of Very High Triglycerides (greater than or equal to500 mg/dL)

  • Goal of therapy: prevent acute pancreatitis
  • Very low fat diets (less than or equal to15% of caloric intake)
  • Triglyceride-lowering drug usually required (fibrate or nicotinic acid)
  • Reduce triglycerides before LDL lowering

 Return to Top

SLIDE 11: Specific Dyslipidemias: Low HDL Cholesterol
Causes of Low HDL Cholesterol (<40 mg/dL)

  • Elevated triglycerides
  • Overweight and obesity
  • Physical inactivity
  • Type 2 diabetes
  • Cigarette smoking
  • Very high carbohydrate intakes (>60% energy)
  • Certain drugs (beta-blockers, anabolic steroids, progestational agents)

 Return to Top

SLIDE 12: Specific Dyslipidemias: Low HDL Cholesterol
Management of Low HDL Cholesterol

  • LDL cholesterol is primary target of therapy
  • Weight reduction and increased physical activity (if the metabolic syndrome is present)
  • Non-HDL cholesterol is secondary target of therapy (if triglycerides greater than or equal to200 mg/dL)
  • Consider nicotinic acid or fibrates (for patients with CHD or CHD risk equivalents)

 Return to Top

SLIDE 13: Specific Dyslipidemias: Diabetic Dyslipidemia

  • Lipoprotein pattern: atherogenic dyslipidemia (high TG, low HDL, small LDL particles)
  • LDL-cholesterol goal: <100 mg/dL
  • Baseline LDL-cholesterol greater than or equal to130 mg/dL
    • Most patients require LDL-lowering drugs
  • Baseline LDL-cholesterol 100-129 mg/dL
    • Consider therapeutic options
  • Baseline triglycerides: greater than or equal to200 mg/dL
    • Non-HDL cholesterol: secondary target of therapy

 Return to Top

Archived page, reproduced from a 2012 copy. It is reference material, not current guidance.